TrialFuture oncology (London, England)2025

FOLFIRINOX-3 plus bevacizumab (bFOLFIRINOX3) in chemo-refractory metastatic colorectal cancer: a multicenter phase II trial.

Hélène Bellio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.